MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease (MIG-HD)
Huntington Disease
About this trial
This is an interventional treatment trial for Huntington Disease focused on measuring Huntington, graft, cellular therapy, striatum
Eligibility Criteria
Inclusion Criteria: Disease clinically declared since at least 1 year ,UHDRS motor > or =5 TFC > or = 10. CAG > or = 36 Age between 18 and 65 Family and socially integrated subject Informed consent. Exclusion Criteria: Severe intellectual deterioration or neuropsychiatric disorders making the follow-up longitudinal too complicated (score MATTIS < 120). Not-observance of the appointments and the symptomatic treatments in pre-surgical period. Intercurrent disease making a surgical operation impossible. Associated disease having a neurological repercussion, intercurrent cerebral lesion with the IRM. Visceral affection engraves, evolutionary, which brings into play the vital forecast or makes risks for general anaesthesia. Mental Affection likely to disturb adhesion with the protocol, and in particular antecedents of hallucinations spontaneous and/or induced by the drugs; antecedents of serious depression having required repeated hospitalizations; antecedents of repeated suicide attempts. Cerebral morphological anomalies, others that those characteristic of the disease, noted with the IRM or the tomodensitometry. Participation in progress, or stopped since less than three months, with a therapeutic protocol of the Huntington's disease Exclusion Criteria (pre-randomization) TFC < 8 Not-observance of the appointments and the symptomatic treatments in pre-surgical period. Intercurrent disease returning the surgery or impossible immunosuppression. v Subject completely isolated with his family and socially.. UHDRS motor < 5. Positives serologies for HIV1, HIV2, AgP24, HTLV1 et 2, HEPATITE B, HEPATITE C, syphilis Psychiatric disorders being able to compromise the follow-up. Signs other than Huntington with the IRM.
Sites / Locations
- Hopital Henri Mondor
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1
2
Early Graft (Early G)
Late Graft (Late G)